Interview with Le Sun, , AbMax
You spent two decades in the US as an academic, executive, and entrepreneur, and then left to return to China and found AbMax. What’s the story behind how you came…
Address: 99Kechuang 14th Street,Building 18,Unit 2,Suite 201B,BDA,Beijing 101111,China
Tel: 86-10-59755729
Web: http://www.antibodychina.com/
AbMax Biotechnology Co., Ltd. was established in 2006 and now is a high-tech enterprise and training base for the national life science and technical personnel. AbMax has the world’s most advanced one-stop technology platform for antibodies and kits researching, which has the monoclonal antibody developed in an average of 46 days with a high success rate of 90%. Moreover, AbMax is also the fastest, best and most competitive service provider of antibody developing in China and one of the world’s best service providers of antibody developing.
In the past six years, AbMax provided services for a number of multinational pharmaceutical companies, the domestic and foreign well-known research units and bio-pharmaceutical enterprises and successfully developed thousands of high quality monoclonal antibodies for the antibody drug, protein, peptide, pathogens, small molecules and other antigens and dozens of kits. AbMax also undertook a dozen government major research projects and established the largest pathogen antibody library for emerging/outbreaking infectious diseases in China.
You spent two decades in the US as an academic, executive, and entrepreneur, and then left to return to China and found AbMax. What’s the story behind how you came…
Servier was one of the first pharmaceutical companies to establish a presence in China back in 1979. How has Servier’s presence evolved alongside China’s huge transformations of the last decades?…
In 2012 Servier China became the 3rd largest affiliate within the Servier group. How has the company progressed since then? Servier-China is a linchpin for Servier. Servier-China has become the…
Since this interview, Michael Ryde has left Lundbeck China and is now working as Commercial Counsellor, Teamleader Health, at the Danish Embassy in Beijing. Oscar Parra currently holds the position…
Could you provide us with an introduction to the company and an overview of operations from the company’s founding through to your position today as a leading biotech company in…
You began your career at Pfizer, working your way up the organizational ladder, when suddenly you decided to come to China back in 2001, well before China was on the…
This interview was conducted with Christopher Stephens, managing partner of Orrick, Herrington & Sutcliffe’s Asia offices with supporting responses from Xiang Wang, lead partner of the firm’s IP pracitce as…
Hooker Cockram is a well established company with an, impressive and rich history. Could you give us some background on both your operations in Australia and your operations in China…
Venturepharm is the most diversified company we’ve seen, throughout many verticals, taking a full-service plus model from venture capital, merchant banking, CRO, CMO, CSO, compound partnering to royalty sharing. That’s…
Could you please introduce the history and main characteristics of Biotech Pharmaceutical? Biotech Pharmaceutical was established in the year 2000, so we are a relatively young company for biopharmaceutical products…
You’ve run a number of life sciences companies now, but before that you started Telephia, an information services provider to the wireless industry. How did you make the jump to…
What initially attracted you to China and what kept you here over the years? I initially became interested in China during university where I studied the country and wrote a…
You have had significant experience at GSK and Pfizer, and also at Frontage Labs doing more entrepreneurial work. What ultimately brought you to Covance? I worked in Big Pharma for…
See our Cookie Privacy Policy Here
